Blood draw for the laboratory asse… for Parkinson's (VaMPiRE, NCT06941012)
Blood test tracks Parkinson progression
- Trial ID
- NCT06941012
- Official Title
- Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution (VaMPiRE)
- Study Acronym
- VaMPiRE
- Goal
- Blood test tracks Parkinson progression
- Status
- RECRUITING
- Sponsor
- Casa di Cura IGEA
- Study Type
- OBSERVATIONAL
- Enrollment
- 1200 participants
- Conditions
- Parkinson Disease (PD)
- Interventions
- Blood draw for the laboratory assessment
Summary For Families
VaMPiRE aims to find whether specific chemical modifications of the α-synuclein protein in blood track Parkinson's progression or can help tell people with PD apart from those without. The team will collect blood samples to measure modified forms of α-synuclein, the protein that misfolds and clumps in Parkinson's, looking for patterns linked to symptom severity or disease stage; this is observational only and does not change medications or interact with levodopa. Adults 18 to 85 are eligible, including people with PD diagnosed by MDS-UPDRS and Hoehn and Yahr stages I,IV while on meds, plus neurologically normal controls, with exclusions for severe cognitive decline, active infections, other confounding neurological conditions, or life‑threatening illnesses.
Locations
- Aristotle University of Thessaloniki, Thessaloniki, Greece
- Casa di Cura Igea, Milan, Mi, Italy
- Instytut Psychiatrii I Neurologii, Warsaw, Poland
- Asociacion Parkinson Madrid, Madrid, Spain
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Blood draw for the laboratory assessment. VaMPiRE aims to find whether specific chemical modifications of the α-synuclein protein in blood track Parkinson's progression or can help tell people with PD apart from those without. The team will collect blood samples to measure modified forms of α-synuclein, the protein that misfolds and clumps in Parkinson's, looking for patterns linked to symptom severity or disease stage; this is observational only and does not change medications or interact with levodopa. Adults 18 to 85 are eligible, including people with PD diagnosed by MDS-UPDRS and Hoehn and Yahr stages I,IV while on meds, plus neurologically normal controls, with exclusions for severe cognitive decline, active infections, other confounding neurological conditions, or life‑threatening illnesses.
- Who can participate?
- Participants must be between 18 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 4 locations.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 7 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.
- How many visits does this trial involve?
- Two blood sample collections for PD participants will occur over a 24-month gap, and non-PD controls will have a single baseline blood sample.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Blood draw (minimally invasive). Confirm the full schedule with the study coordinator.